Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) is a cognitive-behavioral psychotherapy program designed for patients who have posttraumatic stress disorder (PTSD) and a co-occurring alcohol or drug use disorder. COPE represents an integration of two evidence-based treatments: Prolonged Exposure (PE) therapy for PTSD and Relapse Prevention for substance use disorders. COPE is an integrated treatment, meaning that both the PTSD and substance use disorder are addressed concurrently in therapy by the same clinician, and patients can experience substantial reductions in both PTSD symptoms and substance use severity. Patients use the COPE Patient Workbook while their clinician uses the Therapist Guide to deliver treatment. The program is comprised of 12 individual, 60 to 90 minute therapy sessions. The program includes several components: information about how PTSD symptoms and substance use interact with one another; information about the most common reactions to trauma; techniques to help the patient manage cravings and thoughts about using alcohol or drugs; coping skills to help the patient prevent relapse to substances; a breathing retraining relaxation exercise; and in vivo (real life) and imaginal exposures to target the patient's PTSD symptoms.

Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) is a cognitive-behavioral psychotherapy program designed for patients who have posttraumatic stress disorder (PTSD) and a co-occurring alcohol or drug use disorder. COPE represents an integration of two evidence-based treatments: Prolonged Exposure (PE) therapy for PTSD and Relapse Prevention for substance use disorders. COPE is an integrated treatment, meaning that both the PTSD and substance use disorder are addressed concurrently in therapy by the same clinician, and patients can experience substantial reductions in both PTSD symptoms and substance use severity. Patients use the COPE Patient Workbook while their clinician uses the Therapist Guide to deliver treatment. The program is comprised of 12 individual, 60 to 90 minute therapy sessions. The program includes several components: information about how PTSD symptoms and substance use interact with one another; information about the most common reactions to trauma; techniques to help the patient manage cravings and thoughts about using alcohol or drugs; coping skills to help the patient prevent relapse to substances; a breathing retraining relaxation exercise; and in vivo (real life) and imaginal exposures to target the patient's PTSD symptoms.

This state-of-the-science reference and text has given thousands of practitioners and students a strong foundation in understanding and treating addictive disorders. Leading experts address the neurobiology of addictions and review best practices in assessment and diagnosis. Specific substances of abuse are examined in detail, with attention to real-world clinical considerations. Issues in working with particular populations--including polysubstance abusers, culturally diverse patients, older adults, chronic pain sufferers, and others--are explored. Chapters summarize the theoretical and empirical underpinnings of widely used psychosocial and pharmacological treatments and clearly describe clinical techniques. New to This Edition *Incorporates a decade's worth of major advances in research and clinical practice. *Updated for DSM-5. *Many new authors; extensively revised with the latest information on specific biological mechanisms, substances, populations, and treatments. *Chapter on motivational interviewing.

A robust revision, including many entirely new chapters addressing policy, the latest treatment approaches, and special topics, the Sixth Edition of The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment offers a comprehensive and compelling review of this ever-evolving field. New sections address important topics that have gained prominence or become the focus of increased research attention since the Fifth Edition was released. For example, substance use and other psychiatric disorders often co-occur, and the resulting dual disorder is frequently associated with greater symptom severity and worse long-term prognosis than either disorder alone. Accordingly, the section on psychiatric comorbidity covers the epidemiology, assessment, and treatment of substance use disorders (SUDs) that co-occur with psychotic, mood, anxiety, eating, attention-deficit/hyperactivity, or trauma-related disorders. The section devoted to special populations has been revamped, and the topics have been thoroughly updated, some now covered by new contributors and others completely new to this edition. SUDs among women (including perinatal issues), adolescents, patients with chronic pain, sexual and gender minority populations, and older adults are addressed in detailed chapters, as are behavioral addictive disorders and cross-cultural aspects of substance-related and addictive disorders. Finally, the editors have included a section devoted to critically important topics in public health, including the U.S. opioid epidemic, cannabis policy and use, HIV/AIDS and hepatitis C, nicotine and public health, and the prevention of SUDs. New or noteworthy coverage includes the following: • A chapter devoted to the legal and practical aspects of addiction in the occupational sphere, designed for clinicians who treat people with SUDs and/or develop workplace testing programs, employee assistance programs, and occupational drug/alcohol policies for these workers. • A chapter that surveys the growing literature supporting the use of mindfulness, exercise, and other "mind and body" practices (e.g., yoga, acupuncture, tai chi) as complements or alternatives to standard SUD treatment models. • A chapter devoted to hallucinogens, which clarifies their actions, psychoactive effects, historical uses, potential therapeutic benefits, and neural mechanisms, and both identifies their risks and seeks to dispel some of the misconceptions that have continued to surround them. • A suite of chapters devoted to cannabis, encompassing a review of its neurobiology and history, a survey of effective treatment approaches and harm-reduction strategies for cannabis use disorder, and a consideration of evolving public policy around cannabis use. • A trio of chapters devoted to nicotine and tobacco, encompassing a review of neurobiology, a survey of clinical assessment tools, a summary of the research base for effective treatments for tobacco use disorder, and a consideration of public health policy and interventions regarding tobacco use. Evidence-based, down to earth, and meticulously edited, the new Sixth Edition of The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment is an essential resource for clinicians who treat SUDs in a variety of settings—from examining rooms to emergency departments, and from hospitals to recovery facilities.

This state-of-the-science reference and text has given thousands of practitioners and students a strong foundation in understanding and treating addictive disorders. Leading experts address the neurobiology of addictions and review best practices in assessment and diagnosis. Specific substances of abuse are examined in detail, with attention to real-world clinical considerations. Issues in working with particular populations--including polysubstance abusers, culturally diverse patients, older adults, chronic pain sufferers, and others--are explored. Chapters summarize the theoretical and empirical underpinnings of widely used psychosocial and pharmacological treatments and clearly describe clinical techniques. New to This Edition *Incorporates a decade's worth of major advances in research and clinical practice. *Updated for DSM-5. *Many new authors; extensively revised with the latest information on specific biological mechanisms, substances, populations, and treatments. *Chapter on motivational interviewing.